Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Next-Generation Immune Checkpoint Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HHLA2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HHLA2 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View HHLA2 Products |
| Gene Delivery | HHLA2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View HHLA2 Products |
| Benchmark Ab | Anti-HHLA2 (Sequence of IMM40H) Recombinant positive control. |
View HHLA2 Products |
| Validator | HHLA2 siRNA Set For knockdown verification. |
View HHLA2 Products |
| Related Target A | KIR3DL3 Primary co-inhibitory receptor for HHLA2, critical for checkpoint blockade assays. |
View KIR3DL3 Products |
| Related Target B | TMIGD2 Co-stimulatory receptor (CD28H) interacting with HHLA2 in early-stage T-cell activation. |
View TMIGD2 Products |
| Related Target C | B7-H4 B7 family member often co-expressed or mutually exclusive with HHLA2 in PD-L1 negative tumors. |
View B7-H4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Dual-Receptor Binding Differentiation (KIR3DL3 vs TMIGD2) | HEK293-expressed HHLA2 and receptor proteins preserve native glycosylation for precise binding kinetics. |
| Cross-species Cynomolgus Monkey Evaluation | Human and Cynomolgus ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA included for specificity and knockdown validation. |
Live HHLA2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HHLA2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to ADCs and multispecific antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the dual-receptor signaling axis of HHLA2, specifically blocking the inhibitory KIR3DL3 interaction while maintaining or leveraging the TMIGD2 co-stimulatory pathway.
HHLA2 (B7-H7) is widely recognized as a crucial immune checkpoint in PD-L1-negative solid tumors, including triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and ovarian cancers. Because rodents lack a functional HHLA2 ortholog, clinical translation relies heavily on robust non-human primate (NHP) cross-reactivity assays and humanized mouse models, elevating the requirement for high-fidelity recombinant proteins.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (ADCC-enhanced) | ImmuneOnco (IMM40H) | Solid Tumors (TNBC, NSCLC) | Fc-receptor binding assays & Target-density quantification (Need high-purity ECD-Fc) |
| Bispecific / Multi-specific | Elpiscience, Jounce Therapeutics | Immunotherapy-resistant tumors | Dual-receptor blocking assays (Need monomeric HHLA2, KIR3DL3, and TMIGD2) |
| Antibody-Drug Conjugates (ADC) | Preclinical programs | Ovarian & Pancreatic Cancers | Internalization assays and lysosomal degradation assays (Need Lentivirus for stable overexpression) |